Jose S. Pulido

Jose S. Pulido

Auto-generated profile, based on publicly available information

Jose S. Pulido

Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
KCKevin D. Chodnicki
Kevin D. Chodnicki
JPJose S. Pulido
Jose S. Pulido
DHDavid O. Hodge
David O. Hodge
JKJames P. Klaas
James P. Klaas
JCJohn Chen
John Chen

1 September 2018 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SMSasha A. Mansukhani
Sasha A. Mansukhani
ABAndrew J. Barkmeier
Andrew J. Barkmeier
SBSophie J. Bakri
Sophie J. Bakri
RIRaymond Iezzi
Raymond Iezzi
JPJose S. Pulido
Jose S. Pulido
ASArthur J. Sit
Arthur J. Sit

24 April 2017 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
ECElisa Carreras
Elisa Carreras
DSDiva R. Salomão
Diva R. Salomão
JNJeroni Nadal
Jeroni Nadal
SASejal R. Amin
Sejal R. Amin
HRHarish Raja
Harish Raja
JPJose S. Pulido
Jose S. Pulido
To determine the occurrence of macular edema (ME) in vitreoretinal lymphoma (VRL). Retrospective analysis of 17 patients (31 eyes) with VRL. A review of the literature was done as well. Nine patients (15 eyes) had fluorescein angiography and/or optical coherence tomography at presentation. In the ME group (six eyes of four patients), three patients (five eyes) had prior chemotherapy and radiation. Excluding eyes with radiation retinopathy (three eyes), rate of ME was 25% (3/12). When two unirradiated fellow eyes of eyes with radiation retinopathy were also excluded, ME rate was 10% (1/10). Excluding the eyes with intraocular surgery, the rate of ME was 0%. In the group without ME (nine eyes of six patients), one patient (one eye) was treated with chemotherapy and radiation and three patients (five eyes) with chemotherapy. Review of the literature showed that the ME was found between 2 and 60% of cases, but most of the cases with ME had prior interventions. Macular edema in VRL is not uncommon but usually related to prior interventions. Macular edema as an initial presentation of VRL is rare.

1 May 2018 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
LDLauren A. Dalvin
Lauren A. Dalvin
Carol ShieldsCarol Shields
Carol Shields
JPJose S. Pulido
Jose S. Pulido
KSKareem Sioufi
Kareem Sioufi
VCVictoria Cohen
Victoria Cohen
JSJerry A. Shields
Jerry A. Shields
Importance Patients with myotonic dystrophy (MD) have an increased risk of malignancy including uveal melanoma. This case series further explores the association between these 2 diseases. Objective To describe a cohort of patients with uveal melanoma associated with MD, including a case of iris melanoma, and MD-associated uveal melanoma in relatives. Design, Setting, and Participants Retrospective case series at 3 tertiary referral centers (Wills Eye Hospital, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota; and Moorfields Eye Hospital, London, England), between January 1, 2000, and August 31, 2017. The study included 6 patients with MD and uveal melanoma. Main Outcomes and Measures Melanoma response to treatment and development of metastatic disease. Results There were 6 patients, 4 men and 2 women, with MD and uveal melanoma. The mean patient age at melanoma diagnosis was 47 years (median, 43 years; range, 30-67 years), and the tumor involved the choroid in 5 patients (83%) and iris in 1 patient (17%). The diagnosis of MD was known since young adulthood in 2 patients (33%) and was discovered in adulthood in 4 patients (67%). The main clinical features of MD included muscle weakness (n = 5; 83%), myotonia (n = 4; 67%), polychromatic cataract (n = 4; 67%), complications with general anesthesia (n = 4; 67%), myalgia (n = 3; 50%), cardiac arrhythmia (n = 2; 33%), and frontal baldness (n = 2; 33%). Genetic testing revealed MD type 1 (4 of 4 tested patients), and 2 patients demonstrated positive family history of MD with classic clinical features and preferred no testing. Melanoma treatment included plaque radiotherapy (n = 4; 67%), photodynamic therapy (n = 1; 17%), and declined treatment (n = 1; 17%). At follow-up of 6, 6, 41, 42, and 87 months (5 patients), findings included melanoma regression (4 of 5 tumors), melanoma recurrence (1 of 5 tumors), and no metastatic disease (5 of 5 patients). Conclusions and Relevance Six adult patients with MD demonstrated uveal melanoma involving the choroid or iris, emphasizing the association between these 2 diseases. Further research seems warranted to explore the pathogenesis of uveal melanoma in MD. These findings support the consideration of ophthalmic examination for uveal melanoma in patients with MD.

1 July 2019 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
GDGena M. Damento
Gena M. Damento
JPJose S. Pulido
Jose S. Pulido
BABarbara A. Abbott
Barbara A. Abbott
DHDavid O. Hodge
David O. Hodge
LDLauren A. Dalvin
Lauren A. Dalvin

22 February 2021 in Klinische Monatsblätter für Augenheilkunde
Verified
Journal Article
Open access
PDF file
SPSean Platt
Sean Platt
DSDiva R. Salomao
Diva R. Salomao
JPJose Pulido
Jose Pulido
Introduction Little has been published about the choroidal vascular changes that occur years after radiation exposure. The aim of this study was to review the histological changes observed in the choroidal vasculature following radiotherapy for uveal melanoma. Methods Records from a single institution were retrospectively reviewed from June 7, 2007 to June 7, 2017; 101 patients with a diagnosis of uveal melanoma that underwent enucleation had their records reviewed. Out of these, a total of 26 eyes had undergone plaque brachytherapy prior to enucleation, which had been performed at a mean time of 7.2 years (range from 0 years to 30 years) after the initial plaque placement. A histopathologic analysis was conducted on all 26 eyes with special emphasis on the choroidal changes. Of these 26 eyes, 18 demonstrated evidence of radiation-induced vasculopathy. Results Of the 18 eyes, 10/18 (55%) had radiation retinopathy and 16/18 (89%) had radiation choroidal vasculopathy. One patient had a phthisical eye, and the choroid could not be evaluated because the characteristics of the vasculature could not be determined. Nine cases had vitreous hemorrhage (50%), all cases had radiation retinopathy, and 8/9 (89%) had radiation choroidopathy. Of the 16 cases with radiation choroidal vasculopathy, 3/16 (19%) had only intratumoral radiation choroidal vasculopathy, 3/16 (19%) had only extratumoral radiation choroidal vasculopathy, and, thus, 10/16 (32%) had both intratumoral and extratumoral radiation choroidal vasculopathy. In patients with radiation choroidal vasculopathy, 2/16 (13%) had hyalinization of the choroidal vessels. Another 3/16 (19%) cases with radiation choroidal vasculopathy had ectatic vessels. The other 11/16 (68%) had evidence of both hyalinization of the choroidal vessels as well as ectatic vessels in the choroid. Histological evidence of radiation retinopathy and choroidopathy were seen in 69% of eyes enucleated after receiving radiation therapy, which, in some cases, also had vitreous hemorrhage. Polypoidal choroidal vasculopathy, choroidal neovascularization, and retinal choroidal anastomoses (RAP-type lesions) were seen in 12 of the 16 eyes (75%). Discussion/Conclusion Irradiation of malignant tumors of the eye causes not only radiation retinopathy but also radiation choroidopathy. The role of radiation choroidopathy in the subsequent visual loss following radiotherapy and the role of anti-VEGF therapy needs to be recognized and distinguished from radiation retinopathy. Our data adds to the prior limited knowledge that radiation affects the choroid and can induce specific phenotypes similar to the clinical spectrum of CNV, PCV, and RAP.